A Study of the Effectiveness of Venetoclax Tablets in Adult Acute Myeloid Leukemia Participants Ineligible for Standard Induction Therapy in Russian Federation

Acute Myeloid Leukemia (AML) Clinical Trial

— INNOVATE  

Official title:

Prospective Multi-Center Observational Study to Assess Effectiveness of Venclexta (Venetoclax) in Acute Myeloid Leukemia (AML) Patients Ineligible for Standard Induction Therapy in Routine Clinical Practice in Russian Federation (INNOVATE)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04253314
• Other study ID #: P20-147
• Status: Completed
• Start date: March 13, 2020
• Est. completion date: February 16, 2023

Study information

• Verified date: March 2023
• Source: AbbVie
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Acute Myeloid Leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well Venetoclax works to treat AML in adult participants who are ineligible for standard induction therapy in Russian Federation. Venetoclax is a drug approved to treat Acute Myeloid Leukemia. All study participants will receive Venetoclax as prescribed by their study doctor in accordance with approved local label. Adult participants with a diagnosis of AML who are ineligible for standard induction therapy will be enrolled. Around 50 participants will be enrolled in the study in approximately 15 sites in Russian Federation. Participants will receive venetoclax tablets to be taken by mouth daily according to the approved local label. The duration of the study is approximately 18 months. There is expected to be no additional burden for participants in this trial. All study visits will occur during routine clinical practice (approximately every 3 months) and participants will be followed for 18 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 51
• Est. completion date: February 16, 2023
• Est. primary completion date: February 16, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Newly diagnosed acute myeloid leukemia (AML) (de novo or secondary) and eligible to receive Venetoclax as per Russian Ministry of Health label
• Ineligible for standard induction therapy with cytarabine and anthracycline
• Eastern Cooperative Oncology Group (ECOG) score >2
• White blood cell counts <25 x 109 per liter
• Started Venetoclax within 4 weeks of enrolling in study

Exclusion Criteria:

• Acute promyelocytic leukemia
• Contraindications to Venetoclax as listed on the approved local label in Russian Federation
• Neuroleukemia - active central nervous system (CNS) involvement
• Participation in a clinical trial with an investigational drug for AML within 30 days prior to Venetoclax treatment initiation

Related Conditions & MeSH terms

• Acute Myeloid Leukemia (AML)
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute

Locations

Country	Name	City	State
Russian Federation	Regional Clinical Hospital of Irkutsk /ID# 218570	Irkutsk
Russian Federation	Moscow State budget healthcare /ID# 218569	Moscow	Moskva
Russian Federation	Clinical Medico-Sanitary Unit #1 /ID# 222502	Perm
Russian Federation	Almazov National Medical Research Centre /ID# 218571	Sankt-Peterburg
Russian Federation	Russian Research Institute of Hematology and Transfusiology of the FMBA /ID# 229812	Sankt-Peterburg
Russian Federation	Saratov State Medical University n.a. V.I. Razumovskiy /ID# 226059	Saratov	Saratovskaya Oblast
Russian Federation	R.M.Gorbacheva Research Institute of Paediatric Oncology, Haematology and Transp /ID# 224831	St. Petersburg
Russian Federation	Hematology department State budgetary health care institution Volgograd region /ID# 229813	Volgograd	Volgogradskaya Oblast
Russian Federation	Republican Hospital #1 - National Center of Medicine of Sakha (Yakutia) /ID# 224830	Yakutsk
Russian Federation	Sakhalin Regional Clinical Hospital /ID# 222501	Yuzhno-Sakhalinsk

Sponsors (1)

Lead Sponsor	Collaborator
AbbVie

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Survival	Defined as the time (in days) between the date of first Venetoclax intake to date of death.	Approximately 18 months
Secondary	Overall Response Rate	Defined as the percentage of participants with either complete response (CR) or complete response with incomplete hematological recovery (CRi) according to physician's assessment.	Approximately 18 months
Secondary	Best Overall Response Rate	Defined as the percentage of participants with either CR or CRi according to physician's assessment during Venetoclax treatment.	Approximately 18 months
Secondary	Best complete Remission	Defined as the percentage of participants with CR according to physician's assessment during Venetoclax treatment.	Approximately 18 months
Secondary	Time to First Response	Defined as the time (in weeks) between the date of first Venetoclax intake to first response, among CR, CRi, and morphologic leukemia free state (MLSF).	Approximately 18 months
Secondary	Time to Best Response to Treatment	Defined as the time (in weeks) between the date of first Venetoclax intake and the date of hte assessment having documented the best response among CR, CRi, and MLSF.	Approximately 18 months
Secondary	Duration of Response (DOR)	Defined as the time (in weeks) between the date of the first assessment documenting the response to Venetoclax (either CR, CRi, or MLSF) and the date of the first assessment having documented the progression.	Approximately 18 months
Secondary	Event-Free Survival (EFS)	Defined as the time (in weeks) between the date of first Venetoclax intake and the date of the first assessment having documented disease progression (primary refractory disease, or relapse from CR, CRi, or death from any cause).	Approximately 18 months
Secondary	Relapse-Free Survival (RFS)	Defined as the time between the date of CR and the date of the first assessment having documented disease progression or death from any cause.	Approximately 18 months
Secondary	Time to Transfusion Independence	Defined as the time (in weeks) between the date of first Venetoclax intake and the absence of any red blood cell (RBC) or platelet transfusion during any consecutive 8 weeks during the treatment period.	Approximately 18 months
Secondary	Percentage of participants treated with Venetoclax in combination with hypomethylating agents (HMAs)	Defined as the percentage of participants treated with Venetoclax in combination with hypomethylating agents (HMAs).	Approximately 18 months
Secondary	Percentage of participants treated with Venetoclax in combination with low dose cytarabine (LDAC)	Defined as the percentage of participants treated with Venetoclax in combination with low dose cytarabine (LDAC).	Approximately 18 months
Secondary	Percentage of participants treated with Venetoclax in combination with other therapeutic agents	Defined as the percentage of participants treated with Venetoclax in combination with other therapeutic agents	Approximately 18 months
Secondary	Percentage of participants with dose modifications	Percentage of participants with dose modifications.	Approximately 18 months
Secondary	Percentage of participants with dose interruptions	Percentage of participants with dose interruptions	Approximately 18 months
Secondary	Percentage of participants taking concimtant CYP3A medications	Percentage of participants taking concimtant CYP3A medications while treated with Venetoclax.	Approximately 18 months
Secondary	Number of participants with adverse events	An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug.	Approximately 18 months

External Links

•   Related Info.